BRPI0706947A8 - método de preparação de uma composição à base de proteína, e, método de preparação de micropartículas baseadas em proteínas - Google Patents

método de preparação de uma composição à base de proteína, e, método de preparação de micropartículas baseadas em proteínas

Info

Publication number
BRPI0706947A8
BRPI0706947A8 BRPI0706947A BRPI0706947A BRPI0706947A8 BR PI0706947 A8 BRPI0706947 A8 BR PI0706947A8 BR PI0706947 A BRPI0706947 A BR PI0706947A BR PI0706947 A BRPI0706947 A BR PI0706947A BR PI0706947 A8 BRPI0706947 A8 BR PI0706947A8
Authority
BR
Brazil
Prior art keywords
protein
preparing
composition
microparticles
based composition
Prior art date
Application number
BRPI0706947A
Other languages
English (en)
Inventor
Fang Fang
P Malakhov Michael
Original Assignee
Ansun Biopharma Inc
Nexbio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ansun Biopharma Inc, Nexbio Inc filed Critical Ansun Biopharma Inc
Publication of BRPI0706947A2 publication Critical patent/BRPI0706947A2/pt
Publication of BRPI0706947A8 publication Critical patent/BRPI0706947A8/pt
Publication of BRPI0706947B1 publication Critical patent/BRPI0706947B1/pt
Publication of BRPI0706947B8 publication Critical patent/BRPI0706947B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)

Abstract

método de obtençao de uma composiçao a base de proteína, composiçao e artigo de manufatura as microesteras são produzidas ao entrar em contato com uma solução aquosa de uma proteína ou de outra macromolécula com um solvente orgânico e um contraion e resfriar a solução. as microesferas são úteis para preparar produtos farmacêuticos de dimensões definidas.
BRPI0706947A 2006-01-24 2007-01-24 método de preparação de uma composição de micropartícula BRPI0706947B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76200206P 2006-01-24 2006-01-24
US60/762,002 2006-01-24
PCT/US2007/001914 WO2007114881A1 (en) 2006-01-24 2007-01-24 Technology for preparation of macromolecular microspheres

Publications (4)

Publication Number Publication Date
BRPI0706947A2 BRPI0706947A2 (pt) 2011-04-12
BRPI0706947A8 true BRPI0706947A8 (pt) 2019-01-29
BRPI0706947B1 BRPI0706947B1 (pt) 2021-02-09
BRPI0706947B8 BRPI0706947B8 (pt) 2021-05-25

Family

ID=38197716

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0706947A BRPI0706947B8 (pt) 2006-01-24 2007-01-24 método de preparação de uma composição de micropartícula

Country Status (13)

Country Link
US (7) US20070190163A1 (pt)
EP (1) EP1981483A1 (pt)
JP (2) JP5457680B2 (pt)
KR (5) KR101501780B1 (pt)
CN (2) CN104758253A (pt)
AU (1) AU2007233349A1 (pt)
BR (1) BRPI0706947B8 (pt)
CA (2) CA2932997C (pt)
HK (1) HK1210720A1 (pt)
IL (2) IL193001A (pt)
RU (2) RU2464973C2 (pt)
WO (1) WO2007114881A1 (pt)
ZA (1) ZA200807133B (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
US8512710B2 (en) 2002-11-22 2013-08-20 Ansun Biopharma, Inc. Class of therapeutic protein based molecules
WO2004047735A2 (en) * 2002-11-22 2004-06-10 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) * 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
KR101501780B1 (ko) 2006-01-24 2015-03-16 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
EP2063866B2 (en) * 2006-09-18 2017-08-23 GE Healthcare Bio-Sciences Corp. Preparation of glassified biological reagents
JP2010534563A (ja) * 2007-07-24 2010-11-11 ネクスバイオ，インク． マイクロ粒子の作製のための技術
JP5570996B2 (ja) 2007-12-14 2014-08-13 エアロデザインズ インコーポレイテッド エアロゾル化可能な食料品の送達
US9994585B2 (en) 2007-12-31 2018-06-12 Aphios Corporation Transplantation therapies
HRP20161040T1 (hr) 2008-04-29 2016-12-16 Ascendis Pharma Growth Disorders Division A/S Pegilirani rekombinantni spojevi ljudskog hormona rasta
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
US9066894B2 (en) * 2008-09-12 2015-06-30 University Court Of The University Of St. Andrews Carbohydrate binding molecules
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EA201170950A1 (ru) * 2009-01-22 2012-02-28 Санофи Новая комбинация активных ингредиентов, содержащая нестероидное противовоспалительное лекарственное средство и производное колхикозида
JP2013510169A (ja) * 2009-11-06 2013-03-21 ネクスバイオ，インク． 呼吸器管の治療及び予防のための方法、化合物、及び組成物
CA2783296C (en) 2009-12-15 2019-01-15 Ascendis Pharma As Growth hormone composition
WO2011081937A1 (en) 2009-12-15 2011-07-07 Gilead Sciences, Inc. Corticosteroid-beta-agonist-muscarinic antagonist compounds for use in therapy
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
CN107837395A (zh) 2011-02-09 2018-03-27 葛兰素史密斯克莱有限责任公司 冻干制剂
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
US9643996B2 (en) 2011-11-04 2017-05-09 Battelle Memorial Institute Processes for producing protein microparticles
US9034347B2 (en) 2011-12-19 2015-05-19 Arphios Corporation Drug delivery system and method for the treatment of neuro-degenerative disease
WO2013096883A2 (en) 2011-12-23 2013-06-27 The Regents Of The University Of California Spray dry method for encapsulation of biological moieties and chemicals in polymers cross-linked by multivalent ions for controlled release applications
CN102552166A (zh) * 2012-01-09 2012-07-11 北京化工大学 一种溶菌酶/聚(α-氰基丙烯酸异丁酯)载药微球的制备方法
US20130280332A1 (en) * 2012-02-17 2013-10-24 Nexbio, Inc. Methods, Compounds and Compositions for Treatment of Influenza and Parainfluenza Patients
HUE039734T2 (hu) 2012-05-29 2019-01-28 Parion Sciences Inc Nátriumcsatorna-blokkoló aktivitású, dendrimerszerû amino-amid-származékok száraz szem és más nyálkahártya-megbetegedések kezelésére
WO2014005107A2 (en) * 2012-06-28 2014-01-03 Ansun Biopharma, Inc. Microparticle formulations for delivery to the upper and central respiratory tract and methods of manufacture
EP2866792A4 (en) * 2012-06-28 2016-08-17 Ansun Biopharma Inc MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
US20140017318A1 (en) * 2012-07-10 2014-01-16 Kevin O'Connell Method to produce a medicinal product comprising a biologically active protein and the resulting product
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
CN102757726B (zh) * 2012-08-07 2014-04-09 湖南罗比特化学材料有限公司 一种基于天然多羟基糖类制备的水性uv涂料及其方法
US9314519B2 (en) 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
EP2925314B1 (en) 2012-11-28 2020-04-01 Aphios Corporation Combination therapeutics and methods for the treatment of neurodegenerative and other diseases
ES2674665T3 (es) 2012-12-17 2018-07-03 Parion Sciences, Inc. Compuestos de 3,5-diamino-6-cloro-N-(N-(4-fenilbutilo)carbamimidoilo)-pirazina-2-carboxamida
CN108658876A (zh) 2012-12-17 2018-10-16 帕里昂科学公司 3,5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
CA2895512C (en) 2012-12-17 2021-10-19 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives useful for the treatment of diseases favoured by insufficient mucosal hydration
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN103109800B (zh) * 2013-02-26 2015-04-08 广州市锐博生物科技有限公司 壳聚糖纳米粒、防治小菜蛾的生物农药制剂及其制备方法
CN103109798B (zh) * 2013-02-26 2015-04-08 广州市锐博生物科技有限公司 壳聚糖纳米粒、防治红火蚁的生物农药制剂及其制备方法
CN103109799B (zh) * 2013-02-26 2015-04-08 广州市锐博生物科技有限公司 壳聚糖纳米粒、防治斜纹夜蛾的生物农药制剂及其制备方法
US20140342006A1 (en) * 2013-03-15 2014-11-20 Ansun Biopharma, Inc. Methods for Preparing Injectable Protein Microparticle Suspensions
US9393298B2 (en) 2013-03-15 2016-07-19 Intervet Inc. Liquid stable bovine virus vaccines
US9480739B2 (en) 2013-03-15 2016-11-01 Intervet Inc. Bovine virus vaccines that are liquid stable
HK1218720A1 (zh) 2013-04-30 2017-03-10 欧缇托匹克公司 干粉制剂及使用方法
US9630909B2 (en) 2013-06-27 2017-04-25 Mylan Laboratories Ltd Process for the preparation of nepafenac
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
AR097762A1 (es) 2013-09-27 2016-04-13 Intervet Int Bv Formulaciones secas de vacunas que son estables a temperatura ambiente
AR099470A1 (es) 2014-02-17 2016-07-27 Intervet Int Bv Vacunas de virus de aves de corral líquidas
TWI670085B (zh) 2014-02-19 2019-09-01 荷蘭商英特威國際公司 液體穩定之豬病毒疫苗
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
WO2016044656A1 (en) 2014-09-17 2016-03-24 Ansun Biopharma, Inc. Treatment of infection by human enterovirus d68
DE102014114403A1 (de) * 2014-10-02 2016-04-07 Gerresheimer Regensburg Gmbh Stopfen zum Aufsetzen auf ein Anschlusselement einer medizinischen Spritze
IL251906B2 (en) 2014-11-18 2024-04-01 Ascendis Pharma Endocrinology Div A/S Novel polymeric hgh prodrugs
DK3220892T3 (da) 2014-11-21 2021-11-08 Ascendis Pharma Endocrinology Div A/S Langtidsvirkende væksthormondoseringsformer
CN104523659A (zh) * 2015-01-19 2015-04-22 陈长潭 一种胸腺五肽吸入粉雾剂及其制备方法
CN106924715A (zh) * 2015-12-31 2017-07-07 深圳翰宇药业股份有限公司 特利加压素脂质体及其制备方法
CN105963257B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
CN106075403A (zh) * 2016-06-12 2016-11-09 暨南大学 一种胰岛素口服硒纳米制剂及其制备方法
MX2018016393A (es) 2016-07-01 2019-08-12 Univ Leland Stanford Junior Conjugados para la edición de la superficie de la celula diana.
KR20180007322A (ko) * 2016-07-11 2018-01-22 주식회사 삼양바이오팜 고분자 마이크로스피어의 연속 제조방법 및 이를 위한 장치
AU2017300392B2 (en) 2016-07-18 2022-06-16 Tissuegen, Inc. Methods and compositions for maintaining the conformation and structural integrity of biomolecules
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
DE102017104277A1 (de) * 2017-03-01 2018-09-06 Lts Lohmann Therapie-Systeme Ag Transmukosales Verabreichungssystem für Idebenon
US20210252048A1 (en) * 2017-08-25 2021-08-19 AZ solutions, LLC Treatment of lung and airway diseases and disorders
MX2020002119A (es) 2017-08-25 2020-09-18 AZ Solutions LLC Sistema y método para el tratamiento y la irrigación de heridas.
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR102681843B1 (ko) 2017-09-22 2024-07-05 벡추라 인코포레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
KR102914621B1 (ko) 2018-01-03 2026-01-21 팔레온 파마슈티칼스 인크. 재조합 인간 시알리다제, 시알리다제 융합 단백질, 및 이를 사용하는 방법
CN108853492A (zh) * 2018-07-25 2018-11-23 中国医学科学院生物医学工程研究所 治疗自身性免疫疾病的疫苗佐剂及其应用
US20220133630A1 (en) * 2018-10-19 2022-05-05 Ac Pharmaceuticals Co., Ltd. Preparation method of sustained-release microparticles
CN109678964B (zh) * 2018-12-21 2022-02-25 陕西师范大学 一种利托菌素磁珠、制备方法及其应用
CA3131817A1 (en) 2019-03-04 2020-09-10 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
US11419910B1 (en) * 2019-05-10 2022-08-23 Guy J. Guidry Treatment of dermatitis and athlete's foot
CN110664758B (zh) * 2019-10-15 2021-11-30 无锡市人民医院 Pai-cpt还原响应型双药递送纳米粒子的制备方法
CN110923628B (zh) * 2019-11-06 2021-11-26 南京理工大学 一种新型表面团簇分子的制备方法
WO2021151005A1 (en) * 2020-01-22 2021-07-29 Ansun Biopharma, Inc. Inhaled das181 to treat cancer in the lung
US20230346793A1 (en) * 2020-05-28 2023-11-02 Mickey Hu Compositions and Methods for Treating SARS-CoV-2
EP4210692A4 (en) * 2020-09-14 2024-10-02 Zhuhai Beihai Biotech Co., Ltd. Formulations of cabazitaxel
CN112472664B (zh) * 2020-11-17 2022-02-25 中国矿业大学 一种基因靶向治疗的纳米马达-水凝胶体系制备方法
EP4426335A4 (en) * 2021-11-02 2025-12-17 Ansun Biopharma Inc DAS181 VARIANT COMPOSITIONS
CN113893384B (zh) * 2021-11-08 2022-06-21 山东省科学院生物研究所 一种交联壳聚糖微球及其在创面止血修复材料中的应用
CN114377200B (zh) * 2022-01-12 2023-03-24 北京阅色科技发展中心(有限合伙) 面部注射填充用可生物降解亲水高分子微球及制备方法
CN114652734A (zh) * 2022-03-31 2022-06-24 李红梦 一种祛痘的药物组合物及其制备方法
CN115770232A (zh) * 2022-10-28 2023-03-10 苏州大学 一种地佐辛缓释微球及其制备方法
CN117654445B (zh) * 2023-10-20 2026-03-27 广州康盛生物科技股份有限公司 重组蛋白a冻干粉及制备方法
CN120514914B (zh) * 2025-07-22 2025-09-23 成都恒美盛生物科技有限公司 一种高浓高粘可注射软组织填充材料及其制备方法和用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3439089A (en) * 1968-03-27 1969-04-15 Merck & Co Inc Medicated hard candy
US5033252A (en) * 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) * 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5145702A (en) * 1988-09-19 1992-09-08 Opta Food Ingredients, Inc. Hydrophobic protein microparticles and preparation thereof
US6063910A (en) * 1991-11-14 2000-05-16 The Trustees Of Princeton University Preparation of protein microparticles by supercritical fluid precipitation
US5323907A (en) * 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
ATE163230T1 (de) * 1993-03-09 1998-02-15 Epic Therapeutics Inc Makromolekulare mikropartikel und verfahren zu ihrer herstellung
US6090925A (en) * 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6051256A (en) * 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5928706A (en) * 1996-08-09 1999-07-27 Gibson; Suzanne M. Heat-stable protein microparticles and no-shear process for producing same
GB9909066D0 (en) * 1999-04-20 1999-06-16 Oxford Glycosciences Uk Ltd Therapies
GB9910975D0 (en) 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
WO2004047735A2 (en) 2002-11-22 2004-06-10 Mang Yu Broad spectrum anti-viral therapeutics and prophylaxis
US7807174B2 (en) 2002-11-22 2010-10-05 Nexbio, Inc. Class of therapeutic protein based molecules
RU2426590C2 (ru) * 2003-07-18 2011-08-20 Бакстер Интернэшнл Инк. Способы изготовления, применение и композиции небольших сферических частиц, приготовленных регулируемым фазовым разделением
CA2545325C (en) * 2003-11-10 2015-01-13 Uab Research Foundation Compositions for reducing bacterial carriage and cns invasion and methods of using same
JP5103022B2 (ja) * 2004-02-13 2012-12-19 ノッド ファーマシューティカルズ， インコーポレイテッド リン酸カルシウムナノ粒子のコア、生体分子および胆汁酸を含む粒子、ならびにそれらの製造方法および治療用途
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
US8333995B2 (en) 2004-05-12 2012-12-18 Baxter International, Inc. Protein microspheres having injectable properties at high concentrations
KR101501780B1 (ko) 2006-01-24 2015-03-16 넥스바이오, 인코퍼레이티드 고분자 미소 구체들의 조제를 위한 기술
JP2010534563A (ja) 2007-07-24 2010-11-11 ネクスバイオ，インク． マイクロ粒子の作製のための技術

Also Published As

Publication number Publication date
CA2639925C (en) 2016-07-12
CN104758253A (zh) 2015-07-08
US20070190163A1 (en) 2007-08-16
KR20200052386A (ko) 2020-05-14
EP1981483A1 (en) 2008-10-22
US20200197310A1 (en) 2020-06-25
ZA200807133B (en) 2009-05-27
CA2932997C (en) 2019-07-30
KR20080090525A (ko) 2008-10-08
US20150290134A1 (en) 2015-10-15
KR20160147067A (ko) 2016-12-21
IL193001A (en) 2015-08-31
JP2009524667A (ja) 2009-07-02
KR101787939B1 (ko) 2017-10-18
US10583086B2 (en) 2020-03-10
KR20150001844A (ko) 2015-01-06
RU2464973C2 (ru) 2012-10-27
JP6063239B2 (ja) 2017-01-18
US20120116062A1 (en) 2012-05-10
HK1210720A1 (en) 2016-05-06
US8623419B2 (en) 2014-01-07
US20180071219A1 (en) 2018-03-15
KR102109867B1 (ko) 2020-05-13
BRPI0706947A2 (pt) 2011-04-12
KR101501780B1 (ko) 2015-03-16
BRPI0706947B1 (pt) 2021-02-09
IL240268A0 (en) 2015-09-24
US20140134150A1 (en) 2014-05-15
AU2007233349A1 (en) 2007-10-11
JP2013064010A (ja) 2013-04-11
WO2007114881A1 (en) 2007-10-11
BRPI0706947B8 (pt) 2021-05-25
IL193001A0 (en) 2009-02-11
KR102180849B1 (ko) 2020-11-20
US20100166874A1 (en) 2010-07-01
CA2932997A1 (en) 2007-10-11
RU2628807C2 (ru) 2017-08-22
JP5457680B2 (ja) 2014-04-02
KR20170091184A (ko) 2017-08-08
RU2012131203A (ru) 2014-01-20
CN101404980A (zh) 2009-04-08
CA2639925A1 (en) 2007-10-11
RU2008134282A (ru) 2010-02-27

Similar Documents

Publication Publication Date Title
BRPI0706947A8 (pt) método de preparação de uma composição à base de proteína, e, método de preparação de micropartículas baseadas em proteínas
WO2009015286A3 (en) Technology for the preparation of microparticles
BRPI0717404A2 (pt) Processo para produzir polímero modifcado, polímero modificado obtido pelo processo e composição de borracha de borracha contendo o mesmo
BRPI0613429A2 (pt) inibidores de histona desacetilase
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
BRPI0816538A2 (pt) Composição polimérica, processo de preparação de uma composição polimérica, artigo à base de uma composição polimérica, uso de um artigo à base de uma composição polimérica.
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
NO20083153L (no) Kjemiske forbindelser
BRPI0615705A2 (pt) processo para preparar um composto, e, composto
WO2007012979A3 (en) Polylactide compositions and uses thereof
CL2008001897A1 (es) Proceso para la preparacion de 3-halometil-1-metil-1h-pirazol, utiles como intermediario en la produccion de fungicidas; compuestos derivados de 3-halometil-1-metil-1h-pirazol.
BR112013015162A2 (pt) processo para preparar uma composição de revestimento anti-incrustante, composição de revestimento anti-incrustante e seu uso
BR112012013330A2 (pt) composições e métodos para aumentar meia vida do soro de proteínas de fusão fc
NO20080151L (no) Fremgangsmate for fremstilling av en bitumenbase
BR112013031001A2 (pt) método, programa de computador e aparelho
BR112014032514A2 (pt) cartão de chip e método de produção de um cartão de chip
TW200602355A (en) Chemically modified polyaminosaccharide by a hydrocarbyl sultone compound
BR112015028740A2 (pt) processo para preparar dicarbamatos de 1,4:3,6-dianidroexitóis, composto químico precursor, composto químico derivado a partir de pelo menos um dos compostos químicos precursores, e, método de preparação de um composto químico derivado a partir de pelo menos um dos compostos químicos precursores
UY30790A1 (es) Combinacion de dos agentes antiparasitarios, en particular un derivado de 1-aril-4-ciclopropilpirazol y un agente antihelmintico y aplicaciones
BRPI0508610A (pt) derivados de aminoácidos
CY1121438T1 (el) Μεθοδοι για την παρασκευη υδροπηκτων χρησιμοποιωντας ενζυμα λιπασης
EA200970597A1 (ru) Новые бис(диалкиламиды), способ получения и применения
NO20091990L (no) Substituerte pyrazoler, sammensetninger inneholdende disse, fremgangsmate for fremstilling og anvendelse
BR112012013272A2 (pt) processo para a polimerização em massa do lactídeo
NO20062515L (no) Faststoffpreparat som omfatter en insulinsensibilisator, en insulinsekretagog og en polyoksyetylensorbitanfettsyreester

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ANSUN BIOPHARMA, INC. (US)

B25G Requested change of headquarter approved

Owner name: ANSUN BIOPHARMA, INC. (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.7 NA RPI NO 2563 DE 18/02/2020 POR TER SIDO INDEVIDA.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/01/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2811 DE 19-11-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.